Dr. Douglas Sborov is currently an Assistant Professor of Medicine at the Huntsman Cancer Institute at the University of Utah, is the Director of the Multiple Myeloma Program and Division of Hematology Biorepository, Physician Leader of the Multiple Myeloma/Bone Marrow Transplant CTO Program, and was elected as a Huntsman Translational Scholar in 2022. Since arriving to Salt Lake City following his fellowship at The Ohio State University, Dr. Sborov has expanded the HCI Multiple Myeloma Program to include 5 physicians and 3 advanced practice clinicians, and has been instrumental in building the clinical trial portfolio to include phase 1 - 3 trials for patients with multiple myeloma at every step of their disease course. Currently, the HCI MM Program is investigating quadruplet therapies in the newly diagnosed setting, next generation maintenance strategies, and novel therapeutics for patients with relapsed and refractory disease. Overall, Dr. Sborov's mission and the mission of the HCI Multiple Myeloma Program is to deliver compassionate, state-of-the-art treatment for all patients with plasma cell dyscrasias across the Intermountain West region and in collaboration with local and national basic scientists, develop the next generation of drugs that will lead the myeloma community closer to a cure.